Neurocrine Biosciences, Inc. (NBIX) Expected to Announce Quarterly Sales of $24.60 Million
Analysts predict that Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will post sales of $24.60 million for the current quarter, according to Zacks. Seven analysts have issued estimates for Neurocrine Biosciences’ earnings. The highest sales estimate is $31.64 million and the lowest is $19.00 million. The firm is expected to report its next earnings report on Wednesday, November 1st.
On average, analysts expect that Neurocrine Biosciences will report full-year sales of $24.60 million for the current fiscal year, with estimates ranging from $42.10 million to $81.12 million. For the next year, analysts anticipate that the company will post sales of $163.37 million per share, with estimates ranging from $108.00 million to $203.53 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that follow Neurocrine Biosciences.
Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Thursday, August 3rd. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by $0.01. The business had revenue of $6.34 million during the quarter, compared to analysts’ expectations of $0.61 million. During the same quarter last year, the business earned ($0.46) EPS.
NBIX has been the topic of a number of recent research reports. Robert W. Baird restated an “outperform” rating and set a $66.00 price objective on shares of Neurocrine Biosciences in a research note on Friday, April 14th. Piper Jaffray Companies restated an “overweight” rating and set a $80.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, April 17th. BMO Capital Markets restated an “outperform” rating and set a $72.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, April 17th. Needham & Company LLC restated a “buy” rating and set a $62.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, April 17th. Finally, Jefferies Group LLC raised their price objective on Neurocrine Biosciences from $65.00 to $67.00 and gave the stock a “buy” rating in a research note on Monday, May 1st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seventeen have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $68.25.
Shares of Neurocrine Biosciences (NASDAQ:NBIX) opened at 53.85 on Friday. Neurocrine Biosciences has a 12 month low of $37.35 and a 12 month high of $55.38. The firm has a 50-day moving average price of $48.33 and a 200-day moving average price of $46.68. The company’s market capitalization is $4.75 billion.
In related news, insider Dimitri E. Grigoriadis sold 10,000 shares of the business’s stock in a transaction on Tuesday, May 23rd. The stock was sold at an average price of $53.39, for a total transaction of $533,900.00. Following the sale, the insider now owns 107,691 shares in the company, valued at approximately $5,749,622.49. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Christopher Flint Obrien sold 8,734 shares of the business’s stock in a transaction on Thursday, July 27th. The stock was sold at an average price of $50.00, for a total value of $436,700.00. Following the sale, the insider now owns 57,707 shares in the company, valued at approximately $2,885,350. The disclosure for this sale can be found here. Insiders have sold a total of 51,194 shares of company stock worth $2,629,755 in the last 90 days. 4.80% of the stock is currently owned by corporate insiders.
A number of large investors have recently modified their holdings of NBIX. Independent Portfolio Consultants Inc. purchased a new stake in shares of Neurocrine Biosciences during the first quarter worth $106,000. First Mercantile Trust Co. raised its stake in shares of Neurocrine Biosciences by 22.2% in the first quarter. First Mercantile Trust Co. now owns 3,082 shares of the company’s stock worth $133,000 after buying an additional 560 shares in the last quarter. ARS Investment Partners LLC purchased a new stake in shares of Neurocrine Biosciences during the second quarter worth $207,000. Stephens Inc. AR purchased a new stake in shares of Neurocrine Biosciences during the second quarter worth $207,000. Finally, Capstone Asset Management Co. purchased a new stake in shares of Neurocrine Biosciences during the first quarter worth $214,000. Institutional investors and hedge funds own 96.48% of the company’s stock.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.